Literature DB >> 27480850

Intra- and Interlaboratory Agreement in Assessing the In Vitro Activity of Micafungin against Common and Rare Candida Species with the EUCAST, CLSI, and Etest Methods.

J Meletiadis1, E Geertsen2, I Curfs-Breuker2, J F Meis3, J W Mouton4.   

Abstract

The emergence of resistant strains among common and rare Candida species necessitates continuous monitoring of the in vitro susceptibilities of those isolates. We therefore assessed the in vitro activities of micafungin against 1,099 molecularly identified isolates belonging to 5 common and 20 rare Candida species by the EUCAST, CLSI, and Etest methods, assessing both the intralaboratory agreement and the interlaboratory agreement for two centers. The median micafungin EUCAST MICs were as follows, from the lowest to the highest: for Candida albicans, 0.004 mg/liter; for C. glabrata, 0.016 mg/liter; for C. tropicalis, 0.031 mg/liter; for C. krusei, 0.125 mg/liter; for C. parapsilosis, 2 mg/liter. Among rare Candida species, high MICs were found for C. guilliermondii, C. lipolytica, C. orthopsilosis, C. metapsilosis, and C. fermentati. No resistant isolates were found by the CLSI method, whereas resistance rates of 1 to 2% were found by the EUCAST method. Overall, the EUCAST method resulted in MICs 1 to 2 dilutions higher than those found by the CLSI and Etest methods. The intra- and interlaboratory agreement between methods was >92%, except for the interlaboratory agreement between the EUCAST and CLSI methods (81%), where 17 to 31% of the differences were >2 2-fold dilutions for C. albicans, C. glabrata, C. tropicalis, and other rare Candida species and <6% for C. parapsilosis and C. krusei For the other interlaboratory comparisons, the EUCAST method resulted in higher MICs than the Etest method for all species, but <7% of these differences were >2 2-fold dilutions. Overall, the CLSI method resulted in lower MICs than the Etest method, with 11% of all isolates demonstrating >2 2-fold-dilution differences (6 to 20% for C. albicans, C. tropicalis, and rare Candida species; <5% for C. glabrata, C. krusei, and C. parapsilosis) and smaller differences found after 24 h. Despite these differences, categorical agreement was excellent (>97%), with only 1 to 2% very major errors between the EUCAST method and the other two methods.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27480850      PMCID: PMC5038286          DOI: 10.1128/AAC.01027-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST).

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William Hope
Journal:  Clin Microbiol Infect       Date:  2012-05-08       Impact factor: 8.067

3.  Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates.

Authors:  Ana Espinel-Ingroff; Emilia Cantón; Teresa Pelaez; Javier Pemán
Journal:  Diagn Microbiol Infect Dis       Date:  2011-05       Impact factor: 2.803

4.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

5.  Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.

Authors:  M A Pfaller; M Castanheira; D J Diekema; S A Messer; G J Moet; R N Jones
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

6.  Multicenter Comparison of the Etest and EUCAST Methods for Antifungal Susceptibility Testing of Candida Isolates to Micafungin.

Authors:  M-E Bougnoux; E Dannaoui; I Accoceberry; A Angoulvant; E Bailly; F Botterel; S Chevrier; T Chouaki; M Cornet; F Dalle; A Datry; A Dupuis; A Fekkar; J P Gangneux; J Guitard; C Hennequin; Y Le Govic; P Le Pape; D Maubon; S Ranque; M Sautour; B Sendid; J Chandenier
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

7.  Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.

Authors:  Michael A Pfaller; Shawn A Messer; Leah N Woosley; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-05-29       Impact factor: 5.948

8.  Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism.

Authors:  A Prakash; C Sharma; A Singh; P Kumar Singh; A Kumar; F Hagen; N P Govender; A L Colombo; J F Meis; A Chowdhary
Journal:  Clin Microbiol Infect       Date:  2015-11-05       Impact factor: 8.067

9.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).

Authors:  A J Ullmann; M Akova; R Herbrecht; C Viscoli; M C Arendrup; S Arikan-Akdagli; M Bassetti; J Bille; T Calandra; E Castagnola; O A Cornely; J P Donnelly; J Garbino; A H Groll; W W Hope; H E Jensen; B J Kullberg; C Lass-Flörl; O Lortholary; W Meersseman; G Petrikkos; M D Richardson; E Roilides; P E Verweij; M Cuenca-Estrella
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

10.  Comparison between the EUCAST procedure and the Etest for determination of the susceptibility of Candida species isolates to micafungin.

Authors:  Laura Judith Marcos-Zambrano; Pilar Escribano; Cristina Rueda; Óscar Zaragoza; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

View more
  8 in total

1.  In Vitro Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination.

Authors:  J Meletiadis; I Curfs-Breuker; J F Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria.

Authors:  Maria Aigner; Thomas Erbeznik; Martin Gschwentner; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

3.  Fungemia Surveillance in Denmark Demonstrates Emergence of Non-albicans Candida Species and Higher Antifungal Usage and Resistance Rates than in Other Nations.

Authors:  Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

4.  How Yeast Antifungal Resistance Gene Analysis Is Essential to Validate Antifungal Susceptibility Testing Systems.

Authors:  Nicolas Pellaton; Dominique Sanglard; Frederic Lamoth; Alix T Coste
Journal:  Front Cell Infect Microbiol       Date:  2022-05-04       Impact factor: 6.073

5.  Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

Authors:  J M Boonstra; K C van der Elst; A Veringa; E M Jongedijk; R J Brüggemann; R A Koster; G A Kampinga; J G Kosterink; T S van der Werf; J G Zijlstra; D J Touw; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

6.  Analysis of distribution and antibiotic resistance of pathogens isolated from the paediatric population in Shenmu Hospital from 2011-2015.

Authors:  Yang Hui-Min; Wang Yan-Ping; Yong Lin Liu; Bilal Haider Shamsi; He Bo; Meng Xu-Chun
Journal:  J Int Med Res       Date:  2017-08-08       Impact factor: 1.671

Review 7.  Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections.

Authors:  Frederic Lamoth; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2020-12-30

8.  Microbiological Profiles of Ocular Fungal Infection at an Ophthalmic Referral Hospital in Southern China: A Ten-Year Retrospective Study.

Authors:  Yinhui Pei; Xiaoling Chen; Yiwei Tan; Xiuping Liu; Fang Duan; Kaili Wu
Journal:  Infect Drug Resist       Date:  2022-06-22       Impact factor: 4.177

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.